Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Clinical experience with Timentin]

V Vacek1, J Benes, M Kabelková

  • 1Klinika infekcních nemocí 3, LF UK, FN Bulovka, Praha.

Casopis Lekaru Ceskych
|March 25, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disentangling Sources of Momentum Fluctuations in Xe+Xe and Pb+Pb Collisions with the ATLAS Detector.

Physical review letters·2025
Same author

Search for Light Long-Lived Particles in pp Collisions at sqrt[s]=13  TeV Using Displaced Vertices in the ATLAS Inner Detector.

Physical review letters·2024
Same author

Search for the Exclusive W Boson Hadronic Decays W^{±}→π^{±}γ, W^{±}→K^{±}γ and W^{±}→ρ^{±}γ with the ATLAS Detector.

Physical review letters·2024
Same author

Determination of the Relative Sign of the Higgs Boson Couplings to W and Z Bosons Using WH Production via Vector-Boson Fusion with the ATLAS Detector.

Physical review letters·2024
Same author

Studies of the Energy Dependence of Diboson Polarization Fractions and the Radiation-Amplitude-Zero Effect in WZ Production with the ATLAS Detector.

Physical review letters·2024
Same author

Combination of Searches for Higgs Boson Pair Production in pp Collisions at sqrt[s]=13  TeV with the ATLAS Detector.

Physical review letters·2024
Same journal

The personality of professor Otakar Štark in the context of the development of medical genetics in Czechoslovakia in the years 1950-1990.

Casopis lekaru ceskych·2026
Same journal

Václav Náprstek, MD - a forgotten hero.

Casopis lekaru ceskych·2026
Same journal

Professor Otto Piffl, the First Full Professor of Otology and Rhinology at the German University in Prague, passed away 100 years ago.

Casopis lekaru ceskych·2026
Same journal

Ancient sanctuary of Eileithyia, goddess of childbirth, on the island of Paros (Greece).

Casopis lekaru ceskych·2026
Same journal

European Partnership for Personalised Medicine (EP PerMed).

Casopis lekaru ceskych·2026
Same journal

Periodontitis and type 2 diabetes.

Casopis lekaru ceskych·2026
See all related articles

Ticarcillin-clavulanate is a valuable antibiotic for treating Gram-negative and mixed bacterial infections, including sepsis. This combination therapy demonstrates high treatment success rates and good tolerance, making it a cost-effective option.

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Context:

  • Ticarcillin-clavulanate has a long history of use globally for Gram-negative and mixed bacterial infections.
  • Its use in the Czech Republic is less widespread, potentially due to commercial factors rather than medical efficacy.
  • Beta-lactamase-producing microorganisms are a key consideration for this antibiotic combination.

Purpose:

  • To highlight the continued clinical relevance of ticarcillin-clavulanate.
  • To draw attention to this established antibiotic in the Czech medical community.
  • To provide an updated assessment of its therapeutic value.

Summary:

  • A study evaluated 15 patients treated with ticarcillin-clavulanate between 1992-1995.
  • Results were compared to a prior trial (1987-1991) and existing literature.

Related Experiment Videos

  • The mean treatment success rate was approximately 90%.

    • Impact:

    • Ticarcillin-clavulanate remains a highly effective antibiotic for sepsis and severe bacterial infections.
    • It is particularly beneficial for immunocompromised patients.
    • The antibiotic exhibits excellent tolerance and a favorable cost-benefit profile, aligning with international findings.